In summary, 4-6x PET-guided BrECADD is a new EMA-approved treatment option for AS-cHL patients 60-75 years of age. As also recently published in the JCO, 6x N-AVD shows exceptional benefit over 6x Bv-AVD in older S1826 patients with 2y PFS of 89%. Great to have two excellent options to choose from.

The 2-year PFS (91.5%) and OS after 4-6x BrECADD are unprecedented and indicate the high curative potential of an intensified approach in this historically challenging subgroup. Best outcomes in 60-65 years, more dose level reductions in frail patients.

Individual patient trajectories indicate short and anthracycline-sparing treatment with 4x BrECADD in 2/3 of the patients (PET2-negative), while also PET2-positive patients are able to achieve PET-negativity at EOT and favorable long-term outcomes. Improved QoL and Fatigue after 4-6x BrECADD.

Toxicity was mainly hematologic with associated febrile neutropenia (55%), infections, mucositis and gastrointestinal disorders. PNP of mostly grade 1 occurred in 40% No treatment-related mortality was reported. Most symptoms remained stable on and improved after BrECADD (as did functioning scales)

The HD21 Older Cohort was an international, multicenter single-arm phase 2 add-on to the randomized HD21 trial and recruited N=83 evaluable patients. 89% of patients received target no. of 4 or 6 cycles, with frequent use of per-protocol defined dose reductions.